Valneva (AYJ) Q2 2026 Earnings Report

The call presented a mixed picture: materially weaker H1 2026 financials with significant revenue decline, margin compression and one-off manufacturing charges drove a much larger operating loss and EBITDA deterioration. At the same time, the company strengthened its cash position, implemented a restructuring expected to reduce costs and improve H2 cash flow, and highlighted high-impact pipeline developments — most notably strong clinical data and advancing regulatory progress for the Lyme vaccine (Pfizer EMA filing and potential decisions within 12 months), plus progress on IXCHIQ in Brazil and a promising Shigella program. Given the combination of near-term financial strain and clear strategic and clinical catalysts that could be transformative if successful, the overall tone is cautious but constructive.

Valneva confirmed fiscal 2026 guidance of product sales EUR 135–150 million and total revenues EUR 145–160 million, expects a new U.S. Department of Defense IXIARO contract to be signed in the coming months with sales recorded in H2, and said its commercial business should generate positive cash flow while a June restructuring (EUR 3.2m one‑time cost in H1) will have a positive P&L and cash‑flow impact in H2 and beyond. In H1 the company reported product sales of EUR 64.0m (IXIARO EUR 44.0m, DUKORAL EUR 14.7m, IXCHIQ EUR 4.4m, third‑party EUR 1.0m), total revenues EUR 65.8m, cash EUR 121.5m (vs EUR 109.6m at FY‑end 2025), cash used in operations EUR 13.7m, operating loss EUR 49.9m and adjusted EBITDA loss EUR 40.1m; H1 COGS were EUR 59.5m including non‑recurring IXCHIQ cancellation fees of EUR 9.7m and an inventory impairment of EUR 4.5m. Management expects product‑related gross margin to improve in H2 and reiterated potential to become financially self‑sustainable pending regulatory approval of the Lyme vaccine (company noted 2026; CEO later clarified 2027).